HDL-P (Total)

Laboratory assay overview

HDL-P, a measurement of total HDL particle number concentration, may be a better marker of residual risk than chemically measured high-density lipoprotein cholesterol (HDL-C, the so-called “good” cholesterol) or apolipoprotein A-1 (apoA-1, the major protein on HDL), ie, there may be a more consistent inverse association between cardiovascular endpoints and HDL-P compared with HDL-C. Direct quantification of HDL-P concentration by NMR may be useful to refine cardiovascular risk and to evaluate novel HDL-directed therapies. Further studies are needed to clarify the role of HDL-P in clinical practice.

Laboratory assay overview

The Lipoprotein Fractionation, NMR test is used to help assess the risk for cardiovascular disease (CVD) in patients with intermediate or high risk based on traditional or emerging risk factors, and to assess therapeutic response in patients undergoing lipid-lowering therapy.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

Laboratory assay overview

NMR LDL-P is a management tool used in appropriate high-risk patients (type 2 diabetes mellitus, metabolic syndrome, CVD risk equivalent, statin-treated patients) to adjudicate response to treatment and guide adjustment in therapy. It is used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.